LON:VALValiRx Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ValiRx Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 8.25 0.00 (0.00 %) (As of 07/14/2020) Add Compare Share Today's Range 8Now: GBX 8.25▼ 8.4950-Day Range 6.98MA: GBX 7.73▼ 10.2552-Week Range 0.03Now: GBX 8.25▼ 22.90Volume913,065 shsAverage Volume3.82 million shsMarket Capitalization£2.98 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsHeadlines ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ValiRx. Previous Next 1.7 Community Rank Outperform VotesValiRx has received 150 “outperform” votes. (Add your “outperform” vote.)Underperform VotesValiRx has received 282 “underperform” votes. (Add your “underperform” vote.)Community SentimentValiRx has received 65.28% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote “Outperform” if you believe VAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldValiRx does not currently pay a dividend.Dividend GrowthValiRx does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ValiRx insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ValiRx is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ValiRx is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValiRx has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.47 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:VAL Previous Symbol CUSIPN/A CIKN/A Webwww.valirx.com Phone+44-20-30084416Debt Debt-to-Equity Ratio8.97 Current Ratio0.28 Quick Ratio0.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2.04 per share Price / Cash Flow4.05 Book ValueGBX 22 per share Price / Book0.38Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees12 Outstanding Shares36,062,400Market Cap£2.98 million Next Earnings DateN/A OptionableNot Optionable GBX 8.25 0.00 (0.00 %) (As of 07/14/2020) 30 days | 90 days | 365 days | Advanced Chart Receive VAL News and Ratings via Email Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter. ValiRx (LON:VAL) Frequently Asked Questions How has ValiRx's stock been impacted by COVID-19 (Coronavirus)? ValiRx's stock was trading at GBX 0.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VAL shares have increased by 18,233.3% and is now trading at GBX 8.25. View which stocks have been most impacted by Coronavirus. How were ValiRx's earnings last quarter? ValiRx Plc (LON:VAL) released its earnings results on Wednesday, July, 1st. The company reported ($32.50) earnings per share for the quarter. View ValiRx's earnings history. Has ValiRx been receiving favorable news coverage? Media coverage about VAL stock has been trending very negative on Tuesday, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ValiRx earned a news impact score of -3.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. View the latest news about ValiRx. Who are some of ValiRx's key competitors? Some companies that are related to ValiRx include Ovoca Bio (OVB), Naturally Splendid Enterprises (NSP), Crescita Therapeutics (CTX), Medicure (MPH), Synthetic Biologics (SYN), Synthetic Biologics (SYN), biOasis Technologies (BTI), Anatara Lifesciences (ANR), Adalta (1AD), Hemostemix (HEM), Nuvo Pharmaceuticals (NRI), iCo Therapeutics (ICO), Living Cell Technologies (LCT), Medibio (MEB) and IBEX Technologies (IBT). View all competitors. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), Boohoo Group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Solo Oil (SOLO), Cyanconnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR). Who are ValiRx's key executives? ValiRx's management team includes the following people: Dr. Satu Vainikka, Founding Director & CEO (Age 52)Mr. James Gerry Desler, Founding Director & CFO (Age 63)Dr. George Morris, Founding Director & COO (Age 63)Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 63)Mr. Tarquin Edwards, Head of Investor Relations & Communications What is ValiRx's stock symbol? ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL." How do I buy shares of ValiRx? Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ValiRx's stock price today? One share of VAL stock can currently be purchased for approximately GBX 8.25. How big of a company is ValiRx? ValiRx has a market capitalization of £2.98 million. ValiRx employs 12 workers across the globe. What is ValiRx's official website? The official website for ValiRx is www.valirx.com. How can I contact ValiRx? ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416. This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
